Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 701.60 |
---|---|
High | 713.00 |
Low | 701.60 |
Bid | 707.80 |
Offer | 712.60 |
Previous close | 703.80 |
Average volume | 53.33 |
---|---|
Shares outstanding | 109.89m |
Free float | 106.38m |
P/E (TTM) | 18.42 |
Market cap | 81.81bn USD |
EPS (TTM) | 40.42 USD |
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
- Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
- Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
- Regeneron Announces Investor Conference Presentations
- Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
- Regeneron Reports Third Quarter 2024 Financial and Operating Results
- Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
- Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema
- Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
- Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
- Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
More ▼